Research Progress on Dendritic Cells Combined with Cytokine Induced Killer Cells Immunotherapy for Hematological Malignancies --Review.
10.7534/j.issn.1009-2137.2018.04.049
- Author:
Jing SHI
1
;
Tian-Tian MA
1
;
Hua-Sheng LIU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061,Shaanxi Province. China.
2. Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061,Shaanxi Province. China.E-mail: Lhs681995@ 126.com.
- Publication Type:Journal Article
- MeSH:
Combined Modality Therapy;
Cytokine-Induced Killer Cells;
Dendritic Cells;
Hematologic Neoplasms;
Humans;
Immunotherapy;
Immunotherapy, Adoptive
- From:
Journal of Experimental Hematology
2018;26(4):1235-1239
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the incidence of malignant tumors increasing year by year, its treatment has been made great progress on the basis of traditional treatments such as surgery, radiotherapy and chemotherapy, it mainly focuses on rapid development of cellular immunotherapy. The efficacy of dendritic cells combined with cytokine induced killer cell (DC-CIK) immunotherapy for cancer patients is positive, it shows good antitumor activities and the abilities to reconstruct and enhance the immune system of tumor patients in clinical application, it has potential application value. In the treatment of hematologic malignancies which are chemotherapy-based and high-grade malignant, what is the effect of DC-CIK cells immunotherapy for them? In this review, we searched Chinese and abroad literatures from 2012 to 2018 and further focused on 18 clinical research articles about hematologic malignancies in order to analyze the characteristics of DC-CIK cells immunotherapy. It was found that DC-CIK cells can be an effective and promising treatment for patients with hematologic malignancies, and thus, if the process and unified plan are further standardized and improved, the efficacy will be more obvious. For this purpose, this paper reviews the biological characteristic of DC cells, CIK cells and the clinical research progress of DC-CIK cell immunotherapy for hematological malignancies.
